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S U M M A R Y
Objective: To evaluate the efﬁcacy and safety of entecavir (ETV) in patients with advanced
schistosomiasis and hepatitis B virus (HBV) co-infection.
Methods: Sixty-seven patients with advanced schistosomiasis and HBV co-infection were enrolled in this
study. The patients were randomly divided into the ETV treatment group (n = 35) and the control group
(n = 32). The patients in the control group adopted routine supportive therapy for 52 weeks, and those in the
ETV treatment group received ETV at a dose of 0.5 mg once daily on the basis of routine supportive therapy
for 52 weeks. Hepatic ﬁbrosis markers (hyaluronic acid, type III procollagen, type IV collagen, laminin, and
ﬁbronectin), Ishak ﬁbrosis score, alanine transaminase (ALT), HBV DNA, and Child–Pugh score were
compared between the two groups. The intention to treat (ITT) population was used for the analysis. The
measurement data and count data were analyzed by t-test and Chi-square test, respectively.
Results: After 52 weeks of treatment, the hepatic ﬁbrosis markers (hyaluronic acid, type III procollagen,
type IV collagen, laminin, and ﬁbronectin) were signiﬁcantly improved in the ETV treatment group
compared to the control group (all p < 0.05). A 1-point improvement in the Ishak ﬁbrosis score was
found in 25.7% (9/35) of the ETV group, and the mean change from the baseline in the Ishak ﬁbrosis score
was a 0.3-point reduction. The control group showed disease progression in the Ishak ﬁbrosis score.
More patients in the ETV group than in the control group had undetectable serum HBV DNA levels (82.9%
vs. 3.1%, p < 0.05) and ALT normalization (68.6% vs. 18.3%, p < 0.05). The ETV treatment group
demonstrated an improvement in Child–Pugh score at week 52 (3.7 vs. 0.3, p < 0.05). In addition, no
obvious adverse reactions were observed during ETV treatment.
Conclusion: ETV is safe and effective in patients with advanced schistosomiasis and HBV co-infection.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Schistosomiasis, caused by infection with trematode blood ﬂukes
of the genus Schistosoma, is one of the world’s most important
helminth infections in terms of the global burden of human
morbidity and mortality.1,2 Advanced schistosomiasis japonica can
be regarded as an extreme form of chronic Asian schistosomiasis. In
China, advanced schistosomiasis japonica is a chronic disabling
condition associated with portal hypertension, splenomegaly,
ascites, and gastro-esophageal variceal bleeding. These cases are
registered and managed independently from patients with general
chronic schistosomiasis,3,4 and the chronic Schistosoma infection
leads to portal hypertension in these cases, with the resultant* Corresponding author. Tel.: +86 510 68918000.
E-mail address: qywang839@126.com (Y.-W. Qiu).
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within granulomas in portal vein radicles in portal tracts.5 The
prevalence of HBV co-infection in those with advanced schistoso-
miasis japonica is greater than the general population.6,7 Liver
damage will be more serious, as it can present as schistosomiasis
hepatic ﬁbrosis combined with HBV mixed-type hepatic ﬁbrosis and
even hepatocirrhosis.8,9 In the past, the emphasis of treatment has
been on Schistosoma deworming and conventional supplements,
such as albumin, hepatoprotective and diuretic treatment, and
correcting water electrolyte disorders, but the efﬁcacy is far from
satisfactory.10,11 Hence the need for an effective treatment is urgent.
The efﬁcacy and safety of entecavir (ETV) has been shown in chronic
hepatitis B (CHB) and HBV-related decompensated cirrhosis
patients.12,13 The aim of this research was to examine the efﬁcacy
and safety of ETV for schistosomiasis japonica in patients co-infected
with HBV.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Case selection
From January 2009 to March 2011, 67 outpatients and
inpatients with a diagnosis of advanced schistosomiasis japonica
and HBV co-infection at the Fifth People’s Hospital of Wuxi, the
Third People’s Hospital of Kunshan, and the Jiangsu Institute for
Prevention and Treatment of Parasitic Diseases were selected. All
patients had HBV DNA >1000 copies/ml; 18 were HBV e-antigen
(HBeAg)-positive, 50 had ascites, and 17 had giant spleen. Patients
with the following concomitant conditions were excluded: those
co-infected with HIV, hepatitis A, C, D, and E, and those with
alcoholic liver, autoimmune diseases, cholestasis, malignant
tumors, serious heart diseases, and diabetes; pregnant and
lactating women were also excluded. All patients were informed
of the long-term use of medication and the possible adverse effect
of virus drug resistance and changes in the disease. Written
informed consent was obtained from each subject before
treatment.
2.2. Group allocation and treatment
Sixty-seven patients with advanced schistosomiasis japonica
and HBV co-infection were randomly assigned to the ETV
treatment group or the control group. The two groups were
similar in terms of age, sex, ratio of ascites/giant spleen, hepatic
ﬁbrosis markers, Ishak ﬁbrosis score, levels of alanine transami-
nase (ALT) and HBV DNA, ratio of patients with positive e-antigen,
and Child–Pugh score before treatment, and there were no
statistically signiﬁcant differences. Demographic data and clinical
features of the study patients at baseline are shown in Table 1.
Thirty-two patients in the control group adopted routine
supportive therapy (including Schistosoma deworming, diet
regulation, hepatoprotective, diuretic, albumin, anti-infection,
and symptomatic treatment) and 35 patients in the ETV treatment
group received ETV (Baraclude, Sino-America Shanghai Squibb
Pharmaceutical Company) 0.5 mg once a day in addition to
routine supportive treatment. Both groups were treated for 52
weeks.
2.3. Study assessment
Laboratory assessments at baseline and at weeks 12, 24, and 52
included serum hepatic ﬁbrosis markers (hyaluronic acid, type III
procollagen, type IV collagen, laminin, and ﬁbronectin), liverTable 1
Demographic data and clinical features of the study patients at baseline
Control group ETV group p-Value
Patients, n 32 35 >0.05
Sex, male/female, n 22/10 24/11 >0.05
Age, median years (range) 47 (38–65) 46 (39–65) >0.05
Ascites/giant spleen, n 24/8 26/9 >0.05
Markers of hepatic ﬁbrosis mean (SD)
Hyaluronic acid (ng/ml) 362.1 (42.3) 376.7 (34.1) >0.05
Type IV collagen (ng/ml) 253.2 (41.5) 262.2 (42.6) >0.05
Type III procollagen (ng/ml) 256.7 (73.5) 269.2 (70.3) >0.05
Laminin (ng/ml) 246.5 (71.7) 249.7 (76.5) >0.05
Fibronectin (ng/ml) 467.2 (77.4) 473.4 (81.2) >0.05
Ishak ﬁbrosis score, mean (SD) 4.69 (0.69) 4.74 (0.7) >0.05
ALT (U/l), mean (SD) 258.4 (59.3) 267.7 (60.5) >0.05
HBV DNA (log copies/ml), mean (SD) 5.19 (2.45) 5.41 (2.02) >0.05
HBeAg-positive, n/N (%) 8/32 (25.0) 10/35 (28.6) >0.05
Child–Pugh score, mean (SD) 11.6 (2.9) 11.8 (3.2) >0.05
ALT, alanine transaminase; DNA, deoxyribonucleic acid; ETV, entecavir; HBV,
hepatitis B virus; HBeAg, hepatitis B e antigen; SD, standard deviation.function, HBV markers, and HBV DNA. A liver biopsy was
performed at baseline and again after 52 weeks, for all patients.
Therapeutic effects and adverse reactions were observed during
the 52 weeks. Fibrosis markers were tested with a BL-9600
Micropore Plate Chemiluminescent Immunity Analyzer. HBV DNA
was tested with a Light Cycle Gene Fluorescent Quantitative
Analyzer (Swiss Roche). HBV DNA reagent kits were bought from
Shenzhen Pittsburgh based Engineering Co., Ltd, and had a
sensitivity of 1000 copies/ml. HBV markers were determined with
a 1235 Time-Resolved Fluorescent Immunity Analyzer (Finland,
Perkin Elmer Life Science Company). Reagents were provided by
New Wave of Suzhou Bio-technology Co., Ltd. Liver function was
tested with a Hitachi 7600 Auto Bio-chemical Analyzer (Hitachi
High-Tech Company) and its corollary reagents. All liver biopsy
samples were evaluated by a single, central histopathologist.
Fibrosis was assessed with the Ishak modiﬁcation of the histology
activity index (HAI) scoring system, as follows: score 0: no
ﬁbrosis; score 1: ﬁbrous expansion of some portal areas, with or
without short ﬁbrous septa; score 2: ﬁbrous expansion of most
portal areas, with or without short ﬁbrous septa; score 3: ﬁbrous
expansion of most portal areas with occasional portal to portal
bridging; score 4: ﬁbrous expansion of portal areas with marked
bridging (portal to portal as well as portal to central); score 5:
marked bridging (portal to portal and/or portal to central) with
occasional nodules (incomplete cirrhosis); score 6: cirrhosis,
probable or deﬁnite.14,15
2.4. Statistical analysis
Analysis was by intention to treat (ITT) method. Measurement
data were expressed as means  standard deviations (SD).
Differences in measurement data were examined by t-test and
analysis of variance; the numeration data were analyzed by Chi-
square test. The statistical analysis was performed using the
Statistical Program for Social Sciences (SPSS 16.0 for Windows;
SPSS Inc., Chicago, IL, USA); p < 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Changes in hepatic ﬁbrosis markers before and after treatment
Baseline hepatic ﬁbrosis markers (hyaluronic acid, type III
procollagen, type IV collagen, laminin, and ﬁbronectin) were
similar in the two groups (Table 1). Compared with the control
group, those who underwent ETV therapy showed a statistically
signiﬁcant improvement in ﬁbrosis markers after 52 weeks of
treatment (all p < 0.05) (Table 2).
3.2. Results of the Ishak ﬁbrosis score
All biopsy samples with at least two portal areas were evaluated
with the understanding that small biopsy samples tend to score
lower for ﬁbrosis. Baseline biopsy samples had a mean length of
15.1 mm (97% >10 mm), and week 52 biopsy samples had a mean
length of 15.6 mm (98% >10 mm).
After 52 weeks of treatment with ETV, 25.7% (9/35) of
patients showed an improvement in Ishak ﬁbrosis score
(1-point decrease), and the mean change from the baseline
in the Ishak ﬁbrosis score was a 0.3-point reduction. In contrast,
a 1-point progression in the Ishak ﬁbrosis score was found in
53.1% (17/32) of patients in the control group, and the mean
change from the baseline in the Ishak ﬁbrosis score was a 0.5-
point increase. The differences between the control group and
the ETV group were statistically signiﬁcant (all p < 0.05)
(Table 2, Figure 1).
Table 2
Hepatic ﬁbrosis markers, Ishak ﬁbrosis score, Child–Pugh score, and biochemical, virological, and serological responses at week 52 of treatment
Control group ETV group p-Value
Markers of hepatic ﬁbrosis mean (SD)
Hyaluronic acid (ng/ml) 365.7 (64.6) 131.6 (40.2) <0.05
Type IV collagen (ng/ml) 279.1 (42.6) 151.1 (36.4) <0.05
Type III procollagen (ng/ml) 269.3 (45.6) 112.7 (26.3) <0.05
Laminin (ng/ml) 252.2 (76.9) 109.8 (50.5) <0.05
Fibronectin (ng/ml) 423.5 (69.3) 220.1 (68.2) <0.05
Improvement in the Ishak ﬁbrosis score (1-point decrease), n (%) 0/32 (0) 9/35 (25.7) <0.05
Development in the Ishak ﬁbrosis score (1-point increase) 17/32 (53.1) 0/35 (0) <0.05
Mean change from the baseline in the Ishak ﬁbrosis score +0.5 0.3 <0.05
ALT (U/l), mean (SD) 126.3 (45.6) 67.8 (25.2) <0.05
ALT level1 1  upper limit of normal, n (%) 6/32 (18.3) 24/35 (68.6) <0.05
HBV DNA (log copies/ml), mean (SD) 5.27 (2.63) 3.45 (1.86) <0.05
HBV DNA level <1000 copies/ml, n (%) 1/32 (3.1) 29/35 (82.9) <0.05
e antigen seroconversion n/N (%) 0/8 (0) 2/10 (20.0) >0.05
Mean change from baseline in the Child–Pugh score +0.3 3.7 <0.05
ALT, alanine transaminase; DNA, deoxyribonucleic acid; ETV, entecavir; HBV, hepatitis B virus; SD, standard deviation.
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Child–Pugh score of the two groups at week 52 of treatment
After 52 weeks of treatment, the ETV group showed improve-
ment in levels of ALT and HBV DNA, and the mean change from
baseline in the Child–Pugh score at week 52 was 3.7 for the ETV
group and +0.3 for the control group. The differences between the
control group and the ETV group were statistically signiﬁcant (all
p < 0.05) (Table 2).
Table 2 shows that 82.9% of patients in the ETV group achieved
an undetectable HBV DNA level and that 68.6% achieved ALT
normalization after 52 weeks of treatment; compared with control
group, the ETV group showed a statistically signiﬁcant ALT
normalization rate and undetectable HBV DNA rate (<1000
copies/ml) (both p < 0.05). The seroconversion rate of e-antigen
positive patients was similar in the two groups (p > 0.05).
3.4. Adverse effects
Three patients in the control group developed progressive liver
function damage and severe hepatitis at 24, 26, and 42 weeks,
respectively. After using ETV and plasma exchange treatment, two
cases improved and were discharged and one died. No other
serious adverse effects occurred during ETV treatment.
4. Discussion
Patients with advanced schistosomiasis japonica who are co-
infected with HBV are quite common in China. According toS4
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Figure 1. Ishak ﬁbrosis score in the two study groups, before and after treatment.reports, the hepatitis B surface antigen (HBsAg) positive rate in
patients with advanced schistosomiasis japonica may be as high as
16–64%,7,16 which is signiﬁcantly higher than that of the general
population (7.18%).17,18 Routine conventional treatment (includ-
ing schistosomacides, diet regulation, hepatoprotective, diuretic,
albumin, anti-infection, and symptomatic treatment) is given to
most patients with advanced schistosomiasis japonica who are co-
infected with HBV,19 with few reports about nucleotide analogs for
these patients. Some data indicate that for patients with advanced
schistosomiasis who are co-infected with HBV, complications
increase, disease progression is affected, and mortality is
increased.16,20 In this study, liver tissue pathology results showed
that liver ﬁbrosis in most patients was Ishak ﬁbrosis score 4 or
above, and in some cases even active cirrhosis.21 Hence, we believe
that once patients with advanced schistosomiasis are co-infected
with HBV, the liver damage will become more serious on the basis
of the original liver ﬁbrosis, and that liver disease will progres-
sively increase until cirrhosis. Doctors must be aware that patients
with advanced schistosomiasis can often be co-infected with HBV.
Early detection of HBV serological markers is necessary for early
diagnosis in these patients.20 Patients should be considered for
nucleos(t)ide analog treatment when they have positive HBV DNA
(>1000 copies/ml) to relieve the liver ﬁbrosis and inﬂammatory
necrosis and to delay or reduce liver decompensation, cirrhosis,
and its complications.17,22–24
The efﬁcacy and safety of ETV in CHB and cirrhosis patients is
known.12,25 Furthermore, the cumulative probability of genotypic
resistance to ETV was found to be only 1.2% in nucleos(t)ide-naı¨ve
patients over 5 years of treatment.25–27 This study showed that ETV
is also effective and safe for advanced schistosomiasis patients co-
infected with HBV. Results showed that patients in the ETV group
achieved hepatic ﬁbrosis marker amelioration, and 25.7% (9/35) of
patients showed an improvement in the Ishak ﬁbrosis score (1-
point decrease); the mean change from the baseline in the Ishak
ﬁbrosis score was a 0.3-point reduction after 52 weeks of
treatment with ETV. With regard to the improvement in serum
hepatic ﬁbrosis markers, the decrease was found to be relatively
profound; the Ishak ﬁbrosis score did not decrease quite so much.
This is due to the fact that serum ﬁbrosis markers can be inﬂuenced
by the grade of inﬂammation and some liver function indices, such
as serum levels of ALT; an obvious improvement in Ishak ﬁbrosis
score may require longer-term treatment with ETV,26,28–30 which
is consistent with other reports in the literature.
Data showed that 82.9% of patients in the ETV group achieved
an undetectable HBV DNA level and 68.6% of patients achieved ALT
normalization, and the mean change from baseline in Child–Pugh
score at week 52 was 3.7. There was no serious adverse reaction
in the course of treatment. For this reason, we consider that ETV is
L.-H. Huang et al. / International Journal of Infectious Diseases 17 (2013) e606–e609 e609safe and effective in the treatment of patients with advanced
schistosomiasis japonica co-infected with HBV. Antiviral treat-
ment is the basis of anti-ﬁbrosis treatment for these patients.
Because liver ﬁbrosis or cirrhosis occurred in these patients, long-
term ETV medication is recommended to avoid HBV DNA rebound
or deteriorations in condition after medication is stopped.17,22–24
Because the number of cases in the present study was relatively
small and the period of observation was short, further studies are
required to determine its long-term effects and safety.
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